INTERSPORT Austria acquires INTERSPORT Slovenia Group
Strategic move strengthens market position in Central Europe, with over 500 locations in 12 countries and more than € 1 billion in sales

Wels, 15 January 2026 – INTERSPORT Austria is acquiring the INTERSPORT Slovenia Group, headquartered in Slovenia, thereby assuming responsibility for a strong retail network spanning eight countries in Southeast Europe. This acquisition expands the INTERSPORT Austria Group to over 500 locations in twelve countries. As a result, the Group’s external sales will, for the first time, rise to around € 1 billion, underscoring the Group’s growing economic strength in Central and Southeast Europe.
“This acquisition constitutes a strategic milestone for INTERSPORT Austria,” explains Franz Koll, CEO of INTERSPORT Austria. “With this move, we are not only securing our strong foothold in the European sporting goods retail market, but also creating synergies in procurement, digitalization, and logistics. At a time when size, strength, and expertise determine a company’s market position, we are sending a strong signal for the years ahead.”
INTERSPORT is the market leader in Slovenia and also ranks among the top three sporting goods retailers in Croatia, Bosnia and Herzegovina, and Montenegro. In Albania, Kosovo, Serbia, and North Macedonia, the Group operates through franchise partners. The integration will be completed under the umbrella of INTERSPORT Austria GmbH, headquartered in Wels. Local management teams will remain in place.
Tom Foley, CEO of INTERSPORT International Corporation, comments: “We strongly welcome this move. Consolidating our operations in Central and Southeast Europe marks a significant step forward and will boost the expansion of the INTERSPORT brand in a dynamic market environment.”
The completion of the acquisition remains subject to approval by the relevant antitrust authorities. The parties have agreed to keep the purchase price confidential.
Keywords
Contacts
Contact details for media enquiries:
Mag. Irene Haider REICHL UND PARTNER PR GmbH E-Mail: irene.haider@reichlundpartner.com
Mobile: +43 664 85 95 816
pressecenter.reichlundpartner.com
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
VORN Bioenergy announces appointments to leadership team15.1.2026 10:58:53 CET | Press Release
Regensburg. VORN Bioenergy today announces the appointment of Jörg Lennertz as Chief Executive Officer and Manuel Fernández Durán as Chief Financial Officer. Jörg and Manuel together with Michael Wallis Olausson form the new management team. Jörg Lennertz is an experienced leader in the bioenergy sector. Joining VORN Bioenergy from Uniper, he played a key role in building the company’s multi-gigawatt European renewable energy business. Jörg’s experience, from project development through to execution as well as in scaling up, will be valuable for implementing VORN Bioenergy’s ambitious growth strategy across Germany, Italy, the Iberian Peninsula and Poland. Jörg Lennertz succeeds Thorsten Holl who over the past three years, restructured the company, repositioned it, and established its foundations for growth. Jörg Lennertz says: “VORN Bioenergy has decades of experience in realizing and commercially optimizing biomethane assets, and I’m delighted to join them as they enter a new phase o
Vyoma’s first Space Domain Awareness satellite has reached orbit13.1.2026 12:34:15 CET | Press Release
Munich, 13. January 2026 - Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has launched its pioneering surveillance satellite, Flamingo-1, on Sunday, January 11th, 2026 from Vandenberg Space Force Base, California, USA. It was launched aboard the Twilight rideshare mission with SpaceX via Germany-based launch integrator Exolaunch. The satellite was deployed to its operational Sun-synchronous orbit of approximately 500-km in altitude. This marks a significant achievement for the company, which patented the operational concept of an optimized SDA mission. Flamingo-1, equipped with an optical sensor for space-based space surveillance, is a gamechanger for Europe, strengthening SDA efforts directly from orbit. The advanced optical instrument will detect, track and characterize space objects, such as debris and other satellites. Crucially, it will allow Vyoma and its customers to follow up on manoeuvring objects and derive insights into adversary actions
ORTEC expands German healthcare footprint with strategic acquisition of Klages & Partner13.1.2026 09:00:00 CET | Press Release
Zoetermeer, Netherlands - 13 January 2026 - Acquisition adds over 200 healthcare customers and sector-specific workforce management expertise to ORTEC’s portfolio
ESSL leading study to find where and why damaging hail is getting worse12.1.2026 13:38:03 CET | Press Release
Wiener Neustadt, Austria jan 12, 2026 - First comprehensive global study of very large hail in a changing climate reveals contrasting trends and different causes.
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press Release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom